The announcement was made in the presence of Health Minister Dao Hong Lan, Science and Technology Minister Vu Hai Quan, Deputy Foreign Minister Nguyen Minh Hang and representatives of government agencies.
The planned cooperation would involve transferring scientific knowledge, technical expertise, quality management processes and manufacturing capabilities from MSD to VNVC.
|
MSD and VNVC’s representatives and other delegates witness at the signing ceremony on Nov. 18. Photo by Phan Tuan |
The announcement coincided with a visit to Vietnam by MSD executives, including Dr. Marc Gailhardou, president of its Intercontinental Region, and Dr. Andrew Otoo, president of MSD Asia Pacific. VNVC Chairman and CEO Ngo Chi Dung also attended the ceremony.
“MSD looks forward to bringing more than 130 years of global expertise to this planned partnership. We are equally encouraged by VNVC’s local leadership, investment, and long-term vision,” Gailhardou said.
“By combining our respective strengths, we hope to support stronger disease prevention efforts and deliver lasting benefits for the health of the Vietnamese people.”
![]() |
|
Dr. Marc Gailhardou, president of MSD’s Intercontinental Region, speaking at the event. Photo by Phan Tuan |
VNVC Chairman and CEO Ngo Chi Dung said VNVC had worked with MSD for several years, supplying millions of vaccine doses to people in Vietnam annually. The companies are now exploring ways to expand their partnership into technology transfer, domestic manufacturing and localization.
He said high-tech vaccine production required long-term investment in technology, skilled workers and quality management. VNVC had invested in a modern manufacturing facility and was preparing to receive and gradually master advanced technologies, he added.
![]() |
|
VNVC Chairman and CEO Ngo Chi Dung speaking at the signing ceremony. Photo by Phan Tuan |
The planned partnership could help VNVC access advanced manufacturing technologies, strengthen domestic supply and expand vaccine access in Vietnam.
VNVC is investing more than VND2.5 trillion (US$95 million) in the initial phase of a vaccine manufacturing plant in Tay Ninh Province, designed to produce 100-120 million doses annually.
Construction is expected to finish in 2027, with operations scheduled to begin in 2028 and commercial production in 2029. VNVC aims to meet international manufacturing standards, including World Health Organization Good Manufacturing Practices (WHO-GMP), European Union GMP and U.S. Food and Drug Administration current GMP requirements.
The project is part of VNVC’s long-term strategy to develop vaccine manufacturing capabilities and reduce reliance on imports.
VNVC operates nearly 300 vaccination centers nationwide and employs more than 12,000 people. Its network serves children and adults and is supported by cold storage and distribution systems designed to meet Good Storage Practice requirements.
Later on Nov. 18, MSD executives met Deputy Prime Minister Pham Thi Thanh Tra to discuss healthcare priorities and potential cooperation in science, technology and innovation.
The discussions covered collaboration between the government and private sector to strengthen healthcare services and improve access to medicines and vaccines. MSD also outlined its planned cooperation with VNVC, while both sides discussed expanding access to innovative products and supporting the long-term development of Vietnam’s healthcare system.
![]() |
|
VNVC and MSD leaders met with Deputy Prime Minister Pham Thi Thanh Tra (C, in blue) to discuss Vietnam’s healthcare priorities, the role of science, technology, and innovation in advancing healthcare, and opportunities to strengthen collaboration between the government and the private sector. Photo courtesy of VGP |
MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, is a global biopharmaceutical company with more than 130 years of experience developing medicines and vaccines for human and animal health.


